About this trial

The goal of this observational study is to conduct a prospective assessment of the individual Burden of 9 rare skin diseases to assess disability in the broadest sense of the term (psychological, social, economic and physical) for patients and/or families.

Two types of indicators will be used to reach this objective :

1. an individual burden score calculated based on a burden questionnaire created specifically, approved and designed to understand the tendency to changes in care and lifestyles. The burden questionnaire should be used by patients and/or their family themselves in self-assessment. 2. a descriptive analysis of all resources (medical and non-medical) used by the family unit to manage the disease.

Eligibility criteria

Qualifiers

adults or children with a confirmed diagnosis of one of the 9 following rare skin disease: Inherited epidermolysis bullosa, Ichthyosis, Ectodermal dysplasia, Incontinetia Pigmenti, Neurofibromatosis type 1, Albinism, Pemphigus, Mucous membrane pemphigoid or Palmoplantar keratoderma.

prevalent or incident and followed in one the reference/competence centers of the FIMARAD healthcare network,

able to understand a survey (for child, survey should be understood by parents),

having given their signed consent to participate to the cohort RaDiCo-FARD (parents' consent for child).

Disqualifiers

None

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

No trial groups listed

Locations

15
Hôpital Avicenne Bobigny France
Hôpital des Enfants - Groupe Hospitalier Pellegrin Bordeaux France
Hôpital des Enfants - Groupe Hospitalier Pellegrin Bordeaux France
Hôpital Henri-Mondor Créteil France

Sponsors and collaborators

Institut National de la Santé Et de la Recherche Médicale, France

Lead sponsor